Is Moderna, Inc. (MRNA) a Buy, Sell, or Hold?
NASDAQ : MRNA
Moderna, Inc. — Institutional Ownership
$55.63 USD
$1.56 (2.89%)
- Volume
- 4.83M
- Average Volume
- 7.73M
- Market Capitalization
- $22.07B
- P/E Ratio
- -6.83
- Dividend Yield
- 0.00%
- Price Target
- $45.00
- Year High
- $85.60
- Year Low
- $22.28
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.41
Institutional Ownership Summary
Institutional Ownership %
1.77%
Investors Holding
206
change: -590 | last: 796
Increased Positions
103
change: -286 | last: 389
Reduced Positions
48
change: -161 | last: 209
New Positions
45
change: -107 | last: 152
Sold Positions
580
change: 477 | last: 103
Total Calls
55000
Total Puts
139.2K
Put-Call Ratio
2.53
change: 151.5898 | last: 1.015
Total Invested
484M
Beneficial Ownership Filings
| Filing Date | Reporting Person | Amount Beneficially Owned | % of Class |
|---|---|---|---|
| 2026-04-30 | Vanguard Capital Management | 25.93M | 6.53% |
| 2026-03-27 | The Vanguard Group | - | 0.00% |
| 2026-02-09 | BAILLIE GIFFORD & CO | 20.58M | 5.30% |
| 2026-02-06 | FMR LLC | 41.3M | 10.60% |
| 2026-02-05 | FMR LLC | 27.96M | 7.20% |
| 2025-11-05 | FMR LLC | 12.3M | 3.20% |
| 2025-05-12 | FMR LLC | 21.13M | 5.50% |
| 2025-04-30 | BAILLIE GIFFORD & CO | 24.95M | 6.50% |
| 2025-02-12 | BAILLIE GIFFORD & CO | 38.89M | 10.10% |
| 2022-02-14 | Pioneering, Inc. | 37040.0 | 0.10% |
| 2022-02-14 | Ph.D. | 20.01M | 4.90% |
| 2022-02-14 | 7.64% (2) | 31.54M | 7.64% |
| 2022-02-14 | VentureLabs IV, LLC | 11.46M | 2.80% |
| 2022-02-14 | Fund IV, LP | 14.74M | 3.60% |
| 2022-02-14 | IV-Rx, | 2.84M | 0.70% |
| 2022-02-14 | Fund IV General Partner LLC | 17.58M | 4.30% |
| 2022-02-10 | The Vanguard Group - 23-1945930 | 27.43M | 6.76% |
| 2022-02-04 | (1) BlackRock, Inc. | 27.66M | 6.80% |
| 2022-01-26 | Baillie Gifford & Co (Scottish partnership) | 45.77M | 11.00% |
| 2021-07-12 | (1) BlackRock, Inc. | 19.39M | 4.80% |
| 2021-02-16 | VentureLabs IV, LLC | 11.46M | 2.90% |
| 2021-02-16 | Fund IV, LP | 25.9M | 6.50% |
| 2021-02-16 | IV-Rx, | 4.97M | 1.30% |
| 2021-02-16 | Pioneering, Inc. | 37040.0 | 0.10% |
| 2021-02-16 | Ph.D. | 33.14M | 8.40% |
| 2021-02-16 | Fund IV General Partner LLC | 30.87M | 7.80% |
| 2021-02-10 | The Vanguard Group - 23-1945930 | 23.37M | 5.91% |
| 2021-02-10 | Zeneca Inc. | - | 0.00% |
| 2021-02-10 | AstraZeneca PLC | - | 0.00% |
| 2021-02-02 | (1) BlackRock, Inc. | 20.48M | 5.20% |
| 2021-01-27 | Baillie Gifford & Co (Scottish partnership) | 24.31M | 11.00% |
| 2020-02-13 | shares of Common Stock held by a trust for the benefit of Mr. Bancel’s family, which has an independ | 31.6M | 12.00% |
| 2020-02-11 | The Vanguard Group - 23-1945930 | 17.32M | 5.19% |
| 2019-02-14 | 9.3%(2) | 31.14M | 9.30% |
| 2019-02-14 | 10. | 7.97M | 2.40% |
| 2019-02-14 | 10. | 9.25M | 2.80% |
| 2019-01-30 | AstraZeneca PLC | 25.5M | 7.75% |
| 2019-01-30 | Zeneca Inc. | 25.5M | 7.75% |
| 2018-12-21 | Viking Global Opportunities Liquid Portfolio Sub-Master LP | 41578.0 | 0.01% |
| 2018-12-21 | Viking Long Fund Master Ltd. | 4.18M | 1.30% |
| 2018-12-21 | David C. Ott | 17.1M | 5.20% |
| 2018-12-21 | O. Andreas Halvorsen | 17.1M | 5.20% |
| 2018-12-21 | VGE III Portfolio Ltd. | 6.52M | 2.00% |
| 2018-12-21 | Viking Global Equities II LP | 204.02K | 0.06% |
| 2018-12-21 | Viking Long Fund GP LLC | 4.18M | 1.30% |
| 2018-12-21 | Viking Global Opportunities GP LLC | 2.71M | 0.80% |
| 2018-12-21 | Viking Global Opportunities Portfolio GP LLC | 2.71M | 0.80% |
| 2018-12-21 | Viking Global Equities LP | 3.48M | 1.10% |
| 2018-12-21 | Rose S. Shabet | 17.1M | 5.20% |
| 2018-12-21 | Viking Global Opportunities Illiquid Investments Sub-Master LP | 2.67M | 0.80% |
| 2018-12-21 | Viking Global Investors LP | 17.1M | 5.20% |
| 2018-12-21 | Viking Global Performance LLC | 10.2M | 3.10% |
MRNA Enterprise Value History
Annual
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2025-12-31 | $29.49 | 389M | $11.47B | $2.6B | $1.92B | $10.79B |
| 2024-12-31 | $41.58 | 384M | $15.97B | $1.93B | $747M | $14.79B |
| 2023-12-31 | $99.45 | 382M | $37.99B | $2.91B | $1.24B | $36.33B |
| 2022-12-31 | $179.62 | 394M | $70.77B | $3.2B | $1.2B | $68.77B |
| 2021-12-31 | $253.98 | 403M | $102.35B | $6.85B | $916M | $96.42B |
| 2020-12-31 | $104.47 | 381.33M | $39.84B | $2.62B | $237M | $37.45B |
| 2019-12-31 | $19.56 | 330.8M | $6.47B | $235.88M | $132.36M | $6.37B |
| 2018-12-31 | $15.27 | 328.8M | $5.02B | $658.36M | $33.49M | $4.4B |
| 2017-12-31 | $18.60 | 376M | $6.99B | $134.86M | $15.69M | $6.87B |
| 2016-12-31 | $18.60 | 64.09M | $1.19B | $50.08M | $12.5M | $1.15B |
Quarterly
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2026-03-31 | $50.80 | 395M | $20.07B | $1.91B | $1.3B | $19.46B |
| 2025-12-31 | $29.49 | 392M | $11.56B | $2.6B | $1.92B | $10.88B |
| 2025-09-30 | $25.83 | 390M | $10.07B | $1.13B | $1.39B | $10.34B |
| 2025-06-30 | $27.59 | 388M | $10.7B | $1.28B | $741M | $10.17B |
| 2025-03-31 | $28.35 | 386M | $10.94B | $1.62B | $745M | $10.07B |
| 2024-12-31 | $41.58 | 385M | $16.01B | $1.93B | $747M | $14.83B |
| 2024-09-30 | $66.83 | 385M | $25.73B | $1.64B | $1.36B | $25.44B |
| 2024-06-30 | $115.95 | 384M | $44.52B | $2.48B | $1.27B | $43.32B |
| 2024-03-31 | $105.60 | 382M | $40.34B | $2.05B | $1.24B | $39.53B |
| 2023-12-31 | $99.45 | 381M | $37.89B | $2.91B | $1.24B | $36.23B |
| 2023-09-30 | $103.29 | 381M | $39.35B | $2.93B | $1.46B | $37.88B |
| 2023-06-30 | $121.50 | 381M | $46.29B | $3.8B | $1.17B | $43.66B |